BLA 103362 · Berlex Labs
Leukine
Sargramostim · Leukocyte Growth Factor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 5, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Mar 5, 1991
Approved uses
5
Original approval plus efficacy supplements
Registered trials
660
64 Phase 3, 38 recruiting
FAERS reports
1,730
1,272 serious, 255 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 6, 2024.
LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) 1.1 Acute Myeloid Leukemia Following Induction Chemotherapy LEUKINE is indicated to shorten time to neutrophil recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). 1.2 Autologous Peripheral Blood Progenitor Cell Mobilization and Collection LEUKINE is indicated in adult patients with cancer undergoing autologous hematopoietic stem cell transplantation for the mobilization of hematopoietic progenitor cells into peripheral blood for...
Mechanism: Sargramostim (GM-CSF) belongs to a group of growth factors termed colony-stimulating factors which support survival, clonal expansion, and differentiation of hematopoietic progenitor cells. GM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways which include neutrophils, monocytes/macrophages and myeloid-derived dendritic cells. GM-CSF is also capable of activating mature granulocytes and macrophages. GM-CSF is a multilineage factor and, in addition to dose-dependent effects on the myelomonocytic lineage, can promote the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 29, 2018 Supplement 5240 · Efficacy · priority review OrphanLabelLetterReview
- Dec 22, 1995 Supplement 1045 · Efficacy
- Nov 24, 1995 Supplement 1048 · Efficacy
- Sep 15, 1995 Supplement 1033 · Efficacy
- Mar 5, 1991 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- LEUKINE · SARGRAMOSTIM 250UG/ML · VIAL, · Prescription
- LEUKINE · SARGRAMOSTIM 500UG/ML · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sargramostim" as an intervention, any sponsor and status, largest first.
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerPivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498716 · 2,199 participants · Start Aug 2, 2018 · Primary completion Aug 14, 2023
Drug: Atezolizumab; Paclitaxel and 2 more · For: Triple Negative Breast Cancer
Sites: Concord, California; Los Angeles, California; St. Helena, California · 364 sites in all
- Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First RemissionPivotal-lookingCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00002514 · 1,929 participants · Start May 7, 1993 · Primary completion Dec 2006
Drug: sargramostim; asparaginase and 12 more · For: Leukemia
Sites: Aurora, Colorado; Boulder, Colorado; Colorado Springs, Colorado · 94 sites in all
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerPivotal-lookingCompleted
Bavarian NordicIndustry
NCT01322490 · 1,297 participants · Start Nov 28, 2011 · Primary completion Sep 25, 2017
Drug: PROSTVAC-V; PROSTVAC-F and 2 more · For: Prostate Cancer Metastatic
Sites: Anchorage, Alaska; Scottsdale, Arizona; Berkeley, California · 220 sites in all
- Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerPivotal-lookingCompleted
Royal Liverpool University HospitalGovernment (non-federal)
NCT00425360 · 1,110 participants (planned) · Start Sep 2006
Drug: sargramostim; telomerase peptide vaccine GV1001 and 2 more · For: Pancreatic Cancer
Sites: Barnstaple, United Kingdom; Basingstoke, United Kingdom; Boston, United Kingdom · 45 sites in all
- Surgery in Treating Children With NeuroblastomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00003119 · 968 participants · Start Mar 1998 · Primary completion Mar 2006
Drug: filgrastim; sargramostim and 4 more · For: Neuroblastoma
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 235 sites in all
- Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01989572 · 815 participants · Start Feb 23, 2000 · Primary completion Oct 8, 2012
Drug: Sargramostim; Tyrosinase Peptide · For: Iris Melanoma; Medium/Large Size Posterior Uveal Melanoma; Mucosal Melanoma and 17 more
Sites: Birmingham, Alabama; Mobile, Alabama; Scottsdale, Arizona · 148 sites in all
- Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationPivotal-lookingCompleted
Kiniksa Pharmaceuticals International, plcIndustry
NCT04447469 · 814 participants · Start Jul 28, 2020 · Primary completion Nov 12, 2021
Drug: mavrilimumab · For: COVID
Sites: Los Angeles, California; San Diego, California; Chicago, Illinois · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia158
- off label use155
- nausea128
- pain113
- hypotension111
- dyspnoea110
- fatigue94
- diarrhoea87
- death84
- vomiting83
- dizziness63
- chills57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 47 |
| 2006 | 78 |
| 2007 | 65 |
| 2008 | 167 |
| 2009 | 58 |
| 2010 | 68 |
| 2011 | 128 |
| 2012 | 142 |
| 2013 | 92 |
| 2014 | 58 |
| 2015 | 57 |
| 2016 | 78 |
| 2017 | 67 |
| 2018 | 72 |
| 2019 | 48 |
| 2020 | 39 |
| 2021 | 107 |
| 2022 | 76 |
| 2023 | 62 |
| 2024 | 45 |
| 2025 | 68 |
| 2026 | 66 |
Recalls
1 FDA enforcement reports for this application.
Jun 23, 2021 · Class III · Terminated
FAILED STABILITY SPECIFICATION: Out-of-specification (OOS) result observed for Leukine (sargramostim) at the 27-month stability timepoint.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Leukine (Sargramostim)
2024 spending
$3.3M
Beneficiaries
89
456 claims
Per beneficiary
$37,091
$303.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $3,233,408 |
| 2022 | $3,645,063 |
| 2023 | $3,139,334 |
| 2024 | $3,301,073 |
Part B: Leukine (Sargramostim) · HCPCS J2820
2024 spending
$1.4M
Beneficiaries
198
2,540 claims
Per beneficiary
$7,085
2024 ASP limit $59.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,778,909 |
| 2021 | $2,351,486 |
| 2022 | $1,974,305 |
| 2023 | $1,867,290 |
| 2024 | $1,402,912 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Ahluwalia MS, Reardon DA, Abad AP, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Multicenter Study
- Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Roth L, Macdonald JK, McDonald JW, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Sargramostim for active Crohn's disease.
Korzenik JR, Dieckgraefe BK, Valentine JF, et al. · N Engl J Med 2005 · Clinical Trial, Multicenter Study
- Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.
Tazawa R, Ueda T, Abe M, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.
Moghrabi A, Fuchs H, Brown M, et al. · Med Pediatr Oncol 1995 · Clinical Trial
- Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Lazarus HM, Ragsdale CE, Gale RP, et al. · Front Immunol 2021 · Systematic Review
Sponsor: Berlex Labs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.